Trodelvy savings card: as little as $0 an infusion with commercial insurance

Trodelvy is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How to pay the least

Given by your care team

Billed by the clinic

Trodelvy is given by a doctor or nurse, not picked up at a pharmacy.

Ask your care team or your plan what you’d pay before your visit.

Compare every option

Brand nameTrodelvy

Authorized genericsacituzumab govitecan

Regular genericsacituzumab govitecan

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldAsk the pharmacy

Same as Trodelvy?

The original

–

Brand nameThe maker’s card

Gilead Oncology Co-Pay Program

Savings card from Gilead Sciences

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 an infusion

The card takes up to $25,000 a year off your co-pay.

Or call 1-844-876-3358.

In the maker’s words

“Patients may pay as little as $0 out of pocket for TRODELVY, which includes co-pay and coinsurance, up to $25,000 annually…”

From the maker’s offer on trodelvy.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Trodelvy itself, from the same company, sold without the brand name, and usually for less. For now Trodelvy is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Trodelvy is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

TRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated:

Locally Advanced or Metastatic Triple-Negative Breast Cancer

First Line

As a single agent for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor-based therapy.
In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥ 10) as determined by an FDA-authorized test.

Second Line or Later

For the treatment of adult patients with unresectable locally advanced or mTNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease.

Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer

For the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.

Source: the FDA label for Trodelvy (Gilead Sciences, Inc.), June 24, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to the clinic’s billing office.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/trodelvy/